These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

491 related items for PubMed ID: 15780054

  • 1. Osteoprotegerin and RANKL in alcoholic liver cirrhosis.
    Fábrega E, Orive A, García-Suarez C, García-Unzueta M, Antonio Amado J, Pons-Romero F.
    Liver Int; 2005 Apr; 25(2):305-10. PubMed ID: 15780054
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand system in the early post-operative period of liver transplantation.
    Fábrega E, Orive A, García-Unzueta M, Amado JA, Casafont F, Pons-Romero F.
    Clin Transplant; 2006 Apr; 20(3):383-8. PubMed ID: 16824158
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction.
    Crisafulli A, Micari A, Altavilla D, Saporito F, Sardella A, Passaniti M, Raffa S, D'anneo G, Lucà F, Mioni C, Arrigo F, Squadrito F.
    Clin Sci (Lond); 2005 Oct; 109(4):389-95. PubMed ID: 15926884
    [Abstract] [Full Text] [Related]

  • 7. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS).
    Politou M, Terpos E, Anagnostopoulos A, Szydlo R, Laffan M, Layton M, Apperley JF, Dimopoulos MA, Rahemtulla A.
    Br J Haematol; 2004 Sep; 126(5):686-9. PubMed ID: 15327520
    [Abstract] [Full Text] [Related]

  • 8. Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis.
    Lu HK, Chen YL, Chang HC, Li CL, Kuo MY.
    J Periodontal Res; 2006 Aug; 41(4):354-60. PubMed ID: 16827732
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients.
    Kraj M, Owczarska K, Sokołowska U, Centkowski P, Pogłód R, Kruk B.
    Arch Immunol Ther Exp (Warsz); 2005 Aug; 53(5):454-64. PubMed ID: 16314829
    [Abstract] [Full Text] [Related]

  • 13. High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment.
    Amato G, Mazziotti G, Sorvillo F, Piscopo M, Lalli E, Biondi B, Iorio S, Molinari A, Giustina A, Carella C.
    Bone; 2004 Sep; 35(3):785-91. PubMed ID: 15336617
    [Abstract] [Full Text] [Related]

  • 14. Osteoprotegerin (OPG)/RANK-L system in juvenile idiopathic arthritis: is there a potential modulating role for OPG/RANK-L in bone injury?
    Masi L, Simonini G, Piscitelli E, Del Monte F, Giani T, Cimaz R, Vierucci S, Brandi ML, Falcini F.
    J Rheumatol; 2004 May; 31(5):986-91. PubMed ID: 15124262
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The ratio of messenger RNA levels of receptor activator of nuclear factor kappaB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis.
    Fazzalari NL, Kuliwaba JS, Atkins GJ, Forwood MR, Findlay DM.
    J Bone Miner Res; 2001 Jun; 16(6):1015-27. PubMed ID: 11393778
    [Abstract] [Full Text] [Related]

  • 17. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism.
    Stilgren LS, Rettmer E, Eriksen EF, Hegedüs L, Beck-Nielsen H, Abrahamsen B.
    Bone; 2004 Jul; 35(1):256-65. PubMed ID: 15207766
    [Abstract] [Full Text] [Related]

  • 18. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure.
    Ueland T, Yndestad A, Øie E, Florholmen G, Halvorsen B, Frøland SS, Simonsen S, Christensen G, Gullestad L, Aukrust P.
    Circulation; 2005 May 17; 111(19):2461-8. PubMed ID: 15883214
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization.
    Sandberg WJ, Yndestad A, Øie E, Smith C, Ueland T, Ovchinnikova O, Robertson AK, Müller F, Semb AG, Scholz H, Andreassen AK, Gullestad L, Damås JK, Frøland SS, Hansson GK, Halvorsen B, Aukrust P.
    Arterioscler Thromb Vasc Biol; 2006 Apr 17; 26(4):857-63. PubMed ID: 16424351
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.